Category - Executive Moves

Executive Moves

Sigyn Therapeutics names leading nephrologist Dr. H. David Humes to SAB

Sigyn Therapeutics (OTC:SIGY) appointed internationally recognized nephrologist, H. David Humes, M.D., to its scientific advisory board. Dr. Humes recently played an instrumental role in the oversight of preclinical...

March 15, 2022

Executive Moves

Sigyn appoints internationally recognized nephrologist Dr. Alexander Yevzlin to SAB

Sigyn Therapeutics (OTC:SIGY) appointed Alexander Yevzlin, M.D., currently prof. of medicine and director of interventional nephrology at the University of Michigan, to its scientific advisory board. Dr...

March 9, 2022

Executive Moves

Graphite Bio names biotech analyst Alethia Young as CFO

Alethia Young Graphite Bio (NASDAQ:GRPH) appointed Alethia Young as CFO, effective April 1, to oversee the company’s finance, investor relations and corporate communications functions, and to play a key role in...

March 4, 2022

Executive Moves

Sigyn Therapeutics names accomplished financial executive Jeremy Ferrell as CFO

Sigyn Therapeutics (OTC:SIGY) appointed Jeremy Ferrell as CFO, effective March 9, 2022, with overall responsibility for operational finance, budgeting, and financial reporting, as well as helping manage Sigyn’s...

March 2, 2022

Executive Moves

Pipeline Therapeutics appoints Eef Schimmelpennink to board

Closely held Pipeline Therapeutics named Evert (Eef) Schimmelpennink to its board. Mr. Schimmelpennink is a seasoned biotechnology executive with close to 25 years of experience spanning research and development...

February 22, 2022

Executive Moves

Hepion names world-renowned hepatologist, Dr. Eddie Cheung, to lead strategic medical affairs in Asia

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Eddie Cheung, M.D., FACG, to lead the company’s strategic medical affairs in Asia, a newly-created position. Dr. Cheung will explore and identify possible...

February 15, 2022

Executive Moves

Altamira updates RNA therapeutics program with new CDO, NIH grant

Altamira Therapeutics (NASDAQ:CYTO), in a business update on its development activities in RNA therapeutics, appointed Covadonga Pañeda, Ph.D., as chief development officer for RNA therapeutics, effective in early April...

January 13, 2022

Executive Moves

Global medical device executive Kenneth Knudson joins Profound as CCO

Profound Medical (NASDAQ:PROF; TSX:PRN) appointed accomplished global medical device industry veteran, Kenneth Knudson, as chief commercial officer to lead Profound’s worldwide sales, marketing and reimbursement...

January 5, 2022

Executive Moves

Ondine Biomedical appoints renowned Prof Trevor Jones to lead COVID-19 advisory board

Ondine Biomedical (LSE:OBI), appointed Prof. Trevor Jones, CBE FMedSci, to lead a new advisory board on the use of its pioneering photodisinfection-based technology to prevent and treat COVID-19. Ondine’s non-antibiotic...

December 15, 2021

Executive Moves

Talkiatry appoints Vanessa Cao as SVP of operations

In-network psychiatric care provider, Talkiatry, appointed Vanessa Cao as SVP of operations as the company prepares for a national rollout. With more than 10 years of experience in operations, Ms. Cao joins Talkiatry...

November 17, 2021

Category - Executive Moves

Subscribe